Graham L Radford-Smith

Graham L Radford-Smith

UNVERIFIED PROFILE

Are you Graham L Radford-Smith?   Register this Author

Register author
Graham L Radford-Smith

Graham L Radford-Smith

Publications by authors named "Graham L Radford-Smith"

Are you Graham L Radford-Smith?   Register this Author

32Publications

876Reads

31Profile Views

Altered Expression of Angiotensinogen and Mediators of Angiogenesis in Ileal Crohn's Disease.

J Gastrointestin Liver Dis 2016 Mar;25(1):39-48

QIMR Berghofer Medical Research Institute and University of Queensland School of Medicine, Herston Campus;Department of Gastroenterology, Royal Brisbane and Women's Hospital, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15403/jgld.2014.1121.251.chrDOI Listing
March 2016

Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma.

Nat Genet 2015 Sep 3;47(9):987-995. Epub 2015 Aug 3.

Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.3373DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557485PMC
September 2015

Smoking behaviour modifies IL23r-associated disease risk in patients with Crohn's disease.

J Gastroenterol Hepatol 2015 Feb;30(2):299-307

CSIRO Computational Informatics/Australian E-Health Research Centre, Royal Brisbane and Women's Hospital, Brisbane, Victoria, Australia; Preventative Health Flagship, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jgh.12674DOI Listing
February 2015

The effect on melanoma risk of genes previously associated with telomere length.

J Natl Cancer Inst 2014 Oct 17;106(10). Epub 2014 Sep 17.

Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, Leeds Cancer Research UK Centre, University of Leeds, Leeds, UK (MMI, DTB, JCT, MHa, JRM, JANB, JHB); Oncogenomics (NKH), Genetic Epidemiology (NGM), Inflammatory Bowel Diseases Laboratory (GLRS), Cancer Control Group (DCW), Statistical Genetics (SM, MHL), and Molecular Epidemiology (GWM), QIMR Berghofer Medical Research Institute, Brisbane, Australia; INSERM, UMR-946, Genetic Variation and Human Diseases Unit, Paris, France (MB, FD); Université Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Paris, France (MB, FD); Cancer Epidemiology and Services Research, Sydney School of Public Health, University of Sydney, Australia (AEC); Department of Oncology, University of Cambridge, Cambridge, UK (AMD, PDPP); Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (JEL); Centre for Genetic Origins of Health and Disease, Faculty of Medicine, Dentistry and Health Sciences, University of Western Australia, Crawley, Australia (EKM, SVW); Centre for Cancer Biomarkers CCBIO (LAA) and Gade Laboratory for Pathology (AM), Department of Clinical Medicine, University of Bergen, Bergen, Norway; Department of Pathology, Haukeland University Hospital, Bergen, Norway (LAA); Department of Pathology, Molecular Pathology (PAA) and Department of Dermatology (PH), Oslo University Hospital, Rikshospitalet, Oslo, Norway; Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Service de Dermatologie, Université Paris Descartes, Paris, France (MFA); Department of Dermatology (EA) and Oncogenics Unit (EA, EF), Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv, Israel (EA); Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy (GBS, EFPG); Laboratory of Genetics of Rare Hereditary Cancers, San Martino-IST Research Hospital, Genoa, Italy (GBS, EFPG); Division of Cancer Epidemiology and Gene

View Article

Download full-text PDF

Source
https://genepi.qimr.edu.au/contents/p/staff/IlesMM_JNCI_EPUB
Web Search
http://jnci.oxfordjournals.org/cgi/doi/10.1093/jnci/dju267
Publisher Site
http://dx.doi.org/10.1093/jnci/dju267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196080PMC
October 2014

Estimation and partitioning of (co)heritability of inflammatory bowel disease from GWAS and immunochip data.

Hum Mol Genet 2014 Sep 11;23(17):4710-20. Epub 2014 Apr 11.

The Queensland Brain Institute and The University of Queensland Diamantina Institute, Brisbane, QLD, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/hmg/ddu174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119411PMC
September 2014

Hypoxia and Integrin-Mediated Epithelial Restitution during Mucosal Inflammation.

Front Immunol 2013 Sep 11;4:272. Epub 2013 Sep 11.

School of Biomedical Sciences and Pharmacy, University of Newcastle , Newcastle, NSW , Australia ; Hunter Medical Research Institute , New Lambton, NSW , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2013.00272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769679PMC
September 2013

Common PPARγ variants C161T and Pro12Ala are not associated with inflammatory bowel disease in an Australian cohort.

J Gastrointestin Liver Dis 2012 Dec;21(4):349-55

Inflammatory Bowel Diseases Laboratory, Queensland Institute of Medical Research, Herston, Australia.

View Article

Download full-text PDF

Source
December 2012

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.

Nat Genet 2010 Dec;42(12):1118-25

Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.717DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299551PMC
December 2010

Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.

J Gastroenterol Hepatol 2010 Nov;25(11):1732-8

The Centre for Inflammatory Bowel Diseases, Fremantle Hospital, University of Western Australia, Fremantle, Western Australia, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1440-1746.2010.06407.xDOI Listing
November 2010

Anti-tumour necrosis factor-alpha treatment for perianal Crohn's disease in Australia.

Med J Aust 2010 Apr;192(7):375-7

Department of Gastroenterology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.

View Article

Download full-text PDF

Source
April 2010

Role of diet in the development of inflammatory bowel disease.

Inflamm Bowel Dis 2010 Jan;16(1):137-51

Department of Nutrition and Dietetics, Royal Brisbane and Women's Hospital, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ibd.20968DOI Listing
January 2010

The use of indigocarmine spray increases the colonoscopic detection rate of adenomas.

J Gastroenterol 2009 16;44(8):826-33. Epub 2009 May 16.

Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Level 9 Ned Hanlon Building, QLD, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00535-009-0065-3DOI Listing
October 2009

Body composition and muscle strength as predictors of bone mineral density in Crohn's disease.

J Bone Miner Metab 2009 31;27(4):456-63. Epub 2009 Mar 31.

School of Human Movement Studies, Faculty of Health Sciences, The University of Queensland, Brisbane, QLD, 4072, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00774-009-0059-5DOI Listing
September 2009

ACE inhibitors and angiotensin II receptor antagonists in Crohn's disease management.

Expert Rev Gastroenterol Hepatol 2008 Oct;2(5):645-51

Inflammatory Bowel Disease Laboratory, Royal Brisbane and Women's Research Foundation, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474124.2.5.645DOI Listing
October 2008

Novel NOD2 haplotype strengthens the association between TLR4 Asp299gly and Crohn's disease in an Australian population.

Inflamm Bowel Dis 2008 May;14(5):585-90

Inflammatory Bowel Disease Laboratory, Queensland Institute of Medical Research, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ibd.20362DOI Listing
May 2008

The "Fas counterattack" is not an active mode of tumor immune evasion in colorectal cancer with high-level microsatellite instability.

Hum Pathol 2008 Feb 24;39(2):243-50. Epub 2007 Oct 24.

Department of Medicine, National University of Ireland Cork, Clinical Science Building, Cork University Hospital, Wilton, Cork, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2007.06.010DOI Listing
February 2008

Clinically active Crohn's disease in the presence of a low C-reactive protein.

Scand J Gastroenterol 2006 Mar;41(3):306-11

Brisbane IBD Research Group, Department of Medicine and ECMB Laboratory, University of Queensland, Mater Medical Research Institute, South Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00365520500217118DOI Listing
March 2006

Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.

J Pathol 2003 Sep;201(1):46-54

Inflammatory Bowel Disease Laboratory, Royal Brisbane Hospital Foundation Clinical Research Centre, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.1406DOI Listing
September 2003

The pathogenesis of Crohn's disease in the 21st century.

Pathology 2002 Dec;34(6):561-7

Department of Gastroenterology and Hepatology, Royal Brisbane Hospital, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
December 2002